Stock Comparison

JAZZ vs RIGL

Jazz Pharmaceuticals PLC vs Rigel Pharmaceuticals Inc

The Verdict

RIGL takes this one.

JAZZ

Jazz Pharmaceuticals PLC

0.7

out of 10

Distressed

Winner

RIGL

Rigel Pharmaceuticals Inc

7.0

out of 10

Solid Pick

Head-to-Head

$11.9B

Market Cap

$540M

-33.3

P/E Ratio

1.5

-8.3%

Profit Margin

121.5%

-8.8%

Return on Equity

147.0%

1.2

Debt-to-Equity

0.1

Moderate

Overall Risk

Moderate

0.7

DVR Score

7.0

The Deep Dive

JAZZ0.7/10

Jazz Pharmaceuticals remains a well-established biopharmaceutical company with strong execution on its neuroscience and oncology portfolio. The Q4 2025 earnings beat, 10% YoY revenue growth, and 16% YoY Xywav revenue growth demonstrate stable performance. The advancement of zanidatamab (HER2+ GEA) with breakthrough designation and potential H2 2026 approval provides a significant near-term catalys...

Full JAZZ Analysis

RIGL7.0/10

Rigel Pharmaceuticals (RIGL) demonstrates improved prospects for 10x growth, now scoring 70/100. This significant increase from the previous 40/100 is driven by a material shift in financial health: Q1 2026 reported positive net income ($8.7M) and operating cash flow ($2.7M), directly refuting prior concerns of 'persistent cash burn'. Key product sales, TAVALISSE and REZLIDHIA, surged 31% YoY, ind...

Full RIGL Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.